N@N

Thomas Shrader Initiated (BIIB) at Strong Buy and Held Target at $394 on, Aug 7th, 2018

Thomas Shrader of Stifel, Initiated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $394 on, Aug 7th, 2018.

Thomas has made no other calls on BIIB in the last 4 months.

There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Thomas's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Geoff Meacham of "Barclays" Maintained at Hold with Increased Target to $320 on, Wednesday, July 25th, 2018
• Brian Skorney of "Baird" Maintained at Hold with Increased Target to $348 on, Wednesday, July 25th, 2018

These are the ratings of the 4 analyists that currently disagree with Thomas

---

• Carter Gould of "UBS" Maintained at Strong Buy with Increased Target to $395 on, Thursday, July 26th, 2018
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $392 on, Wednesday, July 25th, 2018
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $396 on, Monday, July 23rd, 2018
• Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018

Contributing Sources

---